Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

diluted net loss per common share

include deemed dividends, preferred stock accretion, and changes in

the fair value of warrant liability.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and webcast today, Thursday, August 7, 2008, at 5:00 P.M. EDT to review financial results and recent developments. Interested participants and investors may access the teleconference call by dialing 877-340-7913 (U.S./Canada) or 719-325-4847 (international).

The webcast of the call can be accessed on the Investor section of Amicus' Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Amicus' Web site for 90 days.

A telephonic replay will also be available beginning today at 8 P.M. EDT for seven days through Thursday, August 14. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8324472.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 MEI Pharma, Inc. ... on the clinical development of novel therapies for ... effects of the Company,s investigational drug candidate ME-344 ... when combined with a tyrosine-kinase inhibitor (TKI). In ... be a potent inhibitor of mitochondrial oxidative phosphorylation ...
(Date:5/4/2015)... 4, 2015  Geneia, a company of experienced ... to improve healthcare efficiencies, today announced a first-of-its-kind ... (BNRC) use Geneia,s advanced analytics solution coupled ... quality and lower the cost of patient care. ... claims and utilization data from multiple sources to ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
(Date:5/4/2015)... In a continuing effort to remain ... Per Wickstrom, the founder of Choices Recovery in South ... “Salute to the Oscars” celebration held on February ... floor of the luxurious Beverly Hilton Hotel. , ... sustainable product placement in TV and film, this daylong ...
(Date:5/4/2015)... May 04, 2015 McNeil & ... announces the expansion of coverage for its Emergency ... provider of industry-tailored insurance and proactive risk management to ... we are dedicated to providing our customers with unparalleled ... many evolving needs. We are excited to launch over ...
(Date:5/4/2015)... Orange, NJ (PRWEB) May 04, 2015 ... non-profit organization devoted exclusively to funding innovative lymphoma research ... of education programs, outreach initiatives and patient services – ... at the historic Mayfair Farms in West Orange, NJ ... raised nearly $500,000 for innovative research programs through LRF. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 METTLER ... The Importance of Data Integrity in a GXP ... as guest presenter. This webinar will be presented ... GMT). , Data integrity is a critical component ... to regulatory agencies. However, in recent years an ...
(Date:5/4/2015)... Seattle, WA (PRWEB) May 04, 2015 ... of a collaboration to facilitate development of NM108, a ... disorders that lead to blindness, including Diabetic Retinopathy. ... formulation platform developed by EyeCRO, which can deliver drugs ... a topical eyedrop. , Under the terms of ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3
... it is commonly thought that men with low IQs ... sexual deviance, new research has found the men may ... education previously taken. , A team of North ... without an intellectual disability and a history of sexual ...
... Following a spate of accidental infant,suffocation deaths in Detroit ... awarded a $25,000 grant to support a community-based,initiative called ... safe place for newborns to sleep. The grant is ... is to improve the health status,of all Michigan residents, ...
... and reduce risk of ... medication errors, ... to continually improve patient safety,and staff efficiency, Omnicell, Inc. (Nasdaq: ... and Grant Regional Health,Center, a leading healthcare provider, today announced the ...
... N.C., Oct. 16 As the pace ... their market research,groups to keep up. Effective ... by using customers, markets and competitors as,reference ... according to,research from benchmarking leader Best Practices, ...
... Herley Industries,Inc. (Nasdaq: HRLY ) announced today ... been awarded a contract valued at,approximately $5 million ... produce high power amplifiers for EDO,s CVRJ (CREW,Vehicle ... CEO, commented, "EDO has recently,announced awards with options ...
... vomiting, researchers say , TUESDAY, Oct. 16 (HealthDay News) ... sushi and sashimi -- increases the risk of infection ... severe stomach and intestinal problems such as diarrhea, cramping, ... emergency department, say two cases studies by Japanese researchers. ...
Cached Medicine News:Health News:'Corrective' sex education may make sexual offenders more dangerous 2Health News:Blue Cross Blue Shield of Michigan Awards Grant to Reduce Accidental Infant Suffocations in Wayne County 2Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 2Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 3Health News:Creating an Effective Market Research Group to Generate High-Impact Business Results 2Health News:Herley Industries, Inc. Receives a $5 Million Award from EDO for Electronic Components for IEDs 2Health News:Raw Seafood Poses Digestive Risks 2
... Eppendorf Multipurpose Centrifuges feature ... accommodate a variety of rotors ... are three centrifuges in one: ... centrifuge for cell harvesting; a ...
Inquire...
Inquire...
Inquire...
Medicine Products: